-
Product Insights
NewSA-10 Upstream Project , Croatia
Empower your strategies with our SA-10 Upstream Project , Croatia report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Reasons to buy Gain a gateway to actionable insights and competitive advantage. Acquire a thorough understanding of...
-
Company Insights
NewCaixaBank SA – Digital Transformation Strategies
CaixaBank SA Digital Transformation Strategies Overview CaixaBank is exploring the use of advanced technologies such as blockchain, artificial intelligence, big data, and robotics to increase its operational flexibility and efficiency. AI, big data, cloud, and blockchain are among the key technologies under focus for the company. The annual ICT spending of CaixaBank was estimated at $1.5 billion in 2023. A major share of this spending is earmarked for acquiring software, ICT services, and network and communications from vendors. CaixaBank SA...
-
Product Insights
NewNet Present Value Model: Ipsen SA’s Elafibranor
Empower your strategies with our Net Present Value Model: Ipsen SA's Elafibranor report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: UCB SA’s Bepranemab
Empower your strategies with our Net Present Value Model: UCB SA's Bepranemab report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Innate Pharma SA’s Lacutamab
Empower your strategies with our Net Present Value Model: Innate Pharma SA's Lacutamab report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Cellectis SA’s UCART-22
Empower your strategies with our Net Present Value Model: Cellectis SA's UCART-22 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Oryzon Genomics SA’s Vafidemstat
Empower your strategies with our Net Present Value Model: Oryzon Genomics SA's Vafidemstat report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: ADC Therapeutics SA’s ADCT-602
Empower your strategies with our Net Present Value Model: ADC Therapeutics SA's ADCT-602 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNovacyt SA Pipeline Insight and Competitive Landscape, 2023
Empower your strategies with our Novacyt SA Pipeline Insight and Competitive Landscape, 2023 report and make more profitable business decisions. Novacyt SA (Novacyt) is a medical device company that develops and markets medical cytology solutions. The company offers oncology and infectious disease diagnostic products. It also sells diagnostic reagents used in LBC, oncology, microbiology, haematology and serology testing. Novacyt develops the proprietary technology platform NOVAPREP, a next generation liquid based cytology solution focused on cancer management. The company’s cytology solution...
-
Product Insights
NewGuerbet SA Pipeline Insight and Competitive Landscape, 2023
Empower your strategies with our Guerbet SA Pipeline Insight and Competitive Landscape, 2023 report and make more profitable business decisions. Guerbet SA (Guerbet) is a manufacturer of contrast agents. The company provides a wide range of imaging products, solutions, and services for Computed Tomography (CT)/Cath Lab examinations, magnetic resonance imaging (MRI), and interventional imaging. CT/Cath Lab contrast agents consist of iodinated active ingredients, and few examinations of the digestive tract use barium-based products. MRI imaging uses gadolinium complexes. Guerbet has...